$KVUE

Kenvue posts higher profit, fourth straight sales gain in Q3 earnings

Kenvue reported Q3 adjusted earnings per share of 29 cents, up from 28 cents, and organic sales growth of 2.9%. Revenue exceeded $3.86 billion, matching analyst estimates. Self Care net sales rose 5.9%, while Skin Health and Beauty saw a slight decline. Gross and operating margins improved, and free cash flow increased. CEO Kirk Perry noted progress in operational overhaul and the pending combination with Kimberly-Clark.

Original reporting
Published Oct 30, 2026, 12:22 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 30, 2026, 12:43 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Kenvue posts higher profit, fourth straight sales gain in Q3 earnings — source image
Decision brief

The 30-second read

$KVUEBullishHigh
01

Why it matters

The earnings beat is likely to trigger a short‑term rally in KVUE as investors reassess growth prospects.

02

Market read

First‑hand earnings data for a large‑cap consumer health company, offering actionable insight for traders.

03

What to watch

Potential headwinds from European retailer negotiations and soft skin‑care demand.

Relevance 8/10Novelty 8/10Timing: post-market today

Background

Kenvue, the consumer health spinoff of Kimberly‑Clark, released its third‑quarter earnings, highlighting revenue beat and cash flow strength.

Company-level read

Ticker impact

$KVUEBullishHigh confidence
Context

Kenvue reported Q3 earnings with revenue $3.86B beating estimates and EPS 29¢, providing fresh financial data.

Expected impact

likely upward pressure as investors price in the revenue beat and margin expansion

Evidence & confidence

First report of Q3 results, revenue above consensus and improved margins, which typically drive short‑term price gains.

Market effects

Positive for consumer health and personal care sector as Kenvue shows demand resilience.

U.S. consumer staples may see modest lift.

Limited to markets tracking U.S. consumer health stocks.

Counterpoint

Margin gains may be temporary; cost savings could reverse, and competitive pressure remains.

Key entities

  • Kenvue

    Consumer health products maker reporting Q3 results.

  • Kimberly‑Clark

    Parent company completing combination with Kenvue.

Related articles

$OKTAHighAI 8/10

Okta to Replace Kenvue in S&P 500 Amid Kimberly-Clark Acquisition

S&P Dow Jones Indices announced Okta (OKTA) will replace Kenvue (KVUE) in the S&P 500 on November 4, 2026, due to Kenvue's acquisition by Kimberly-Clark (KMB). Kenvue's valuation is $48.7B, with a $21.01 per-share consideration. Glaukos (GKOS) will replace Okta in the S&P MidCap 400, and McGrath RentCorp (MGRC) will replace Glaukos in the S&P SmallCap 600. Loar Holdings (LOAR) will replace LiveRamp (RAMP) in the S&P SmallCap 600 due to LiveRamp's acquisition by Publicis Groupe (PU4.DE).

$KVUEMedAI 8/10

Kenvue Q3 2026: Sales Up 3.2% to $3.89B, Adjusted EPS $0.29, No Guidance on Kimberly-Clark Deal

Kenvue Inc. (NYSE: KVUE) reported Q3 2026 net sales of $3.89B, up 3.2% YoY, with adjusted EPS of $0.29. Gross and operating margins improved, driven by supply-chain savings and tariff refunds. Self Care and Essential Health segments grew, while Skin Health and Beauty lagged. Free cash flow rose to $1.6B. No guidance was provided due to the pending Kimberly-Clark deal.

$KVUEMed

Kenvue Delivers Fourth Consecutive Quarter of Sales Growth

Kenvue reported Q3 2026 net sales growth of 3.2% and organic sales growth of 2.9%, marking four consecutive quarters of sales growth. CEO Kirk Perry attributed the performance to strong execution, productivity initiatives, and brand investments. Skin Health & Beauty sales declined slightly, while Hair Care saw double-digit growth. Self Care segment increased by 5.9%. The company is on track for its business transformation and upcoming combination with Kimberly-Clark.

$KVUEHighAI 9/10

Kenvue Q3 Sales Rise 3.2% as EPS Increases 5%

Kenvue reported Q3 2026 net sales growth of 3.2% to $4.1B, with EPS up 5% to $0.22. Organic sales rose 2.9%, driven by volume growth and value realization. Gross and operating margins improved, while cash flow increased. The company did not provide guidance due to its pending merger with Kimberly-Clark.

$KVUEMed

Kenvue 3Q 2026: Revenue $3.89B, EPS $0.22— 10-Q Summary

Kenvue reported Q3 2026 net sales of $3.89B, up 3.2% YoY, with net income increasing 8% to $430M and EPS rising 4.8% to $0.22. Organic sales grew 2.9% in the quarter, with Self Care sales up 5.9% and Essential Health up 2.5%. The company aims for $200M in annual savings and is divesting feminine-care businesses as part of merger regulatory steps.